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ABSTRACT 
 
Aims: To examine the properties of hydrazide compounds shown to inhibit Mycobacterium 
tuberculosis. To identify properties that affect efficiency of bacterial inhibition. 
Study Design: Utilizing data from previous studies of compounds that inhibit Mycobacterium 
tuberculosis, then statistical and pattern recognition methods are applied to identify 
interrelationships. 
Place and Duration of Study: Department of Chemistry, Durham Science Center, University of 
Nebraska at Omaha, from January 2016 to July 2016. 
Methodology: Interrelationships of pharmacological properties were identified by use of various 
pattern recognition techniques, such as hierarchical cluster analysis and path analysis. Molecular 
properties and descriptors for all compounds were determined, with additional characteristics such 
as structure scaffolding and functional group position was accomplished. Statistical analysis, 
including Pearson r correlation, Mann-Whitney test, one-way ANOVA, Kruskal-Wallis, and 
descriptive statistics were determined. Multiple regression analysis of molecular property values 
allows prediction of similar compounds. Determination of any numerical outliers was accomplished 
by applying Grubb’s test.                                                                                                      
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Results: Mycobacterium tuberculosis inhibiting compounds contained either an aromatic ring or 
were non-aromatic structures (no ring). There was weak negative correlation of MIC to formula 
weight. The average formula weight, polar surface area, and Log P, is 183.55 grams/mole, 63.70 
A2, and 0.768, respectively. Values of MIC ranged from 14.7 µg/mL to 100 µg/mL. Extent of 
bacterial inhibition was similar between aromatics to non-aromatics. No outliers were identified by 
Grubb’s test for all values of MIC taken together. Path analysis showed polar surface area to have 
most effect on MIC. 
Conclusion: The measured level of growth inhibition MIC, showed strong positive relationship to 
polar surface area, number of hydroxyl and amine groups, oxygen and nitrogen atoms. Two 
aromatic compounds having a pyridine ring were found to be most similar to isoniazid. Aromatic 
and non-aromatic compounds showed similar levels of bacterial inhibition overall. 
 
 
Keywords: Tuberculosis; TB; hydrazides; Mycobacterium tuberculosis. 
 
ABBREVIATIONS 
  
PSA: Polar surface area; FW: Formula weight; nOHNH: Number of hydroxyl and amine groups;             
nON: Number of oxygen and nitrogen atoms; MIC: Minimum inhibitory concentration; MDR-TB: Multi-
drug resistant tuberculosis; XDR-TB: Extensively drug resistant tuberculosis; CNS: Central nervous 
system; TDR-TB: Totally drug-resistant tuberculosis. 
 
1. INTRODUCTION  
 
The clinical treatment and control of tuberculosis 
disease is significantly threatened with the 
appearance of multi-drug resistant tuberculosis 
(MDR-TB) and extensively drug resistant 
tuberculosis (XDR-TB) [1]. The appropriate use 
of second-line drugs is required to treat cases of 
MDR-TB, and to inhibit the proliferation of XDR-
TB [1]. The World Health Organization has been 
surveilling the rate of resistant tuberculosis in 
numerous countries, and an estimate of over four 
million cases of MDR-TB is thought to emerge in 
2006 [1]. The tuberculosis bacterial infection of 
the central nervous system (CNS) accounts for 
about 1% of all cases of tuberculosis [2]. The 
CNS case of tuberculosis is highly devastating, 
causing high mortality and neurological damage 
[2]. Measurement of this extra pulmonary 
infection within the United States showed that 
5% to 10% of these cases involved the CNS [2].  
CNS tuberculosis exists primarily as tuberculous 
meningitis, and less as encephalitis, intracranial 
tuberculoma, or tuberculous brain abscess [2]. 
 
Treatment of CNS associated tuberculosis 
infection requires a minimum of 10 months of 
treatment [3]. Early treatment of CNS 
tuberculosis is vital and dramatically improves 
patient outcome [4]. In incidences of tuberculosis 
meningitis there is a thick gelatinous exudate in 
the proximity of basal cisterns, brainstem, and 
cerebellum [2,4]. Treatment of tuberculosis 
meningitis is usually followed with treatment          
with isoniazid, rifampicin, pyrazinamide, and 
ethambutol for a period of two months, then 
isoniazid and rifampicin only for an additional ten 
months [5]. The addition of aspirin in treatment 
has been shown to improve mortality rates by 
inhibiting complicating infarctions [6]. Children, 
especially those less than 1 year of age, are 
particularly at risk for CNS tuberculosis [7].   
 
Totally drug-resistant tuberculosis (TDR-TB) 
have been identified in Italy, Iran, India, and 
South Africa [8]. TDR-TB is described as 
resistance to all first-line and second-line drugs 
utilized in clinical treatment [8]. Extra pulmonary 
tuberculosis can coexist simultaneously with 
pulmonary tuberculosis [9]. It is the high lipid 
content of the bacterial membrane that 
contributes to the difficulty of treating 
tuberculosis [10]. Patients having latent 
tuberculosis infection are not considered to be 
contagious to others, but 10% of these cases will 
move on to develop active tuberculosis infection 
[11]. Various symptoms of CNS involved 
tuberculosis infection are the following:  brain 
abscesses, encephalopathy, encephalitis, and 
arteritis [12]. 
 
With threats such as multi-drug resistant, 
extensively drug resistant, and totally drug 
resistant tuberculosis, the investigation and 
development of new clinical drugs are an urgent 
necessity to confront these forms of tuberculosis. 
Novel structure scaffolding of compounds have 
been evaluated for bacterial inhibition and 
potential use as clinical drugs, have been shown 
to be effective for inhibiting tuberculosis 
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[13,14,15]. The design and testing of novel 
molecular structures has been shown to be 
effective inhibitors of other bacterial infections 
such as Staphylococcus aureus [16,17,18], and 
Escherichia coli [19,20,21,22]. Clearly, the 
investigation of new molecular structures have 
benefitted the identification of powerful inhibitors 
of bacterial infection. Novel analytical methods to 
identify functional groups have accompanied the 
generation of novel hydrazide-type drug designs 
that assist in synthesis, quality control, and assay 
[23]. This study examines the contribution of drug 
molecular properties to the effectiveness of their 
inhibition of Mycobacterium tuberculosis.  
 
2. METHODOLOGY  
 
2.1 Properties and Molecular Modeling 
 
Molecular properties and descriptors of all 
compounds were determined by utilizing 
Molinspiration (Molinspiration Cheminformatics, 
Nova ulica 61, SK-0026 Slovensky Grob, Slovak 
Republic) http://www.molinspiration.com/cgi-
bin/properties. Additional characteristics was 
accomplished through the use of ACD 
ChemSketch Modeling v. 12.01 (Advanced 
Chemistry Development, 110 Yonge Street, 
Toronto Ontario, M5C 1T4 Canada, 
http://www.molinspiration.com/services/search. 
html).   
 
2.2 Pattern Recognition and Multivariate 
Analysis 
 
Numerical properties can demonstrate underlying 
patterns and relationships which can be identified 
by use of various pattern recognition techniques. 
Hierarchical cluster analysis cluster analysis was 
performed by KyPlot version 2.0 beta 15 
(copyright Koichi Yoshioka 1997-2001). Various 
statistical tests were performed by PAST version 
2.06 (copyright Oyvind Hammer, D.A.T. Harper 
1999-2008).  Path analysis was determined by 
utilzing OpenStat (copyright William Miller, 
September 11, 2008).  
 
2.3 Various Statistical Analysis of Data 
 
Statistical analysis, including Pearson r 
correlation and descriptive statistics were 
accomplished by Microsoft EXCEL 
v.14.0.6112.5000 (EXCEL Professional plus 
2010).  Multiple regression analysis of molecular 
property values was accomplished by GraphPad 
Instat version 3.00 (GraphPad Software, Inc., 
San Diego, California USA; www.graphpad.com).  
Determination of any numerical outliers was 
accomplished by applying Grubb’s test (also 
known as extreme studentized deviate) 
http://www.graphpad.com/quickcalcs/index.cfm.  
Mann-Whitney test, Kruskal-Wallis test, one-way 
ANOVA, F and T test, were determined by PAST 
version 2.06. 
 
3. RESULTS AND DISCUSSION 
 
3.1 Structure and Properties  
 
The investigation of novel drugs for the treatment 
of tuberculosis is a vitally important endeavor 
due to the burden of the disease worldwide and 
the appearance of multi-drug resistant, 
extensively drug resistant, and totally drug 
resistant tuberculosis [1,8]. In this study, a group 
of novel hydrazide compounds have been 
compared to the first-line drug isoniazid for 
efficiency of Mycobacterium tuberculosis 
inhibition. The effectiveness of inhibition is 
measured by in vitro method, with effectiveness 
measured as MIC for comparison.   
 
The structures of all compounds tested in vitro 
and evaluated [13,14,15], are presented in Fig. 1, 
for comparison to the first-line drug isoniazid 
(compound 14) and other hydrazide compounds.  
Characteristic of all the compounds shown is the 
hydrazide group (-C(=O)-NHNH2) that is a 
substituent of the molecular structures. 
Compounds 1, 2, 3, 4, 8, 9, 10, 13, and 14 
(isoniazid) have aromatic ring (contain 
conjugated planar ring systems), with 
compounds 8, 13, and 14 being heterocyclic 
compounds having a nitrogen atom substitution 
within the ring (see Fig. 1).   
 
Compounds 5, 6, 7, and 11 have aliphatic chains 
(chain of –CH2-), albeit compound 5 has a 
terminal bromine atom.  Aliphatic groups are 
nonpolar and hydrophobic, with hydrophobicity 
increasing with increasing number of C atoms in 
the hydrocarbon chain. Hydrophobicity reduces 
aqueous solubility and increases lipophilic 
character.  More lipophilic character is generally 
viewed as increasing the ability of a drug to 
penetrate the membrane bilayer.  Each of these 
compounds have the hydrazide group (-C(=O)-
NHNH2).  Compounds 1, 2, 4, 9, and 10 have 
substituents covalently bonded to an aromatic 
ring: methyl-, methyl-, chloro-, 2-methylpropyl-, 
and acetate, respectively. Compounds 12 has 
two hydrazide groups. All other compounds have 
only a single hydrazide group.  
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Fig. 1. Compounds previously shown to inhibit the growth of Mycobacterium tuberculosis 
[13,14,15]. All compounds possess the hydrazide group (-C(=O)NHNH2). Compounds 1, 2, 3, 4, 
8, 9, 10, 13, and 14 are aromatic organic compounds. Compounds 5, 6, 7, 11, and 12 are non-
aromatic organic compounds. Compound 12 bears two hydrazide functional groups 
 
The comparison of aromatic and nonaromatic 
molecular scaffolding for delivery of the 
hydrazide group will elucidate the effects upon 
the molecular properties of the drug, such as: 
Log P, polar surface area, formula weight, 
number of hydroxyl, and number of amine 
groups. 
 
In turn, these aspects of the molecular structure 
have been shown to influence the drug likeness 
(i.e. a qualitative concept for how drug like a 
compound in respect to factors like 
bioavailability). Various criteria have been 
developed to screen a potential drug for drug 
likeness, such as the rule of five, which states 
that poor absorption or permeation is more likely 
for a drug candidate when there are more than 
[24]: 1) Five hydrogen bond donors; 2) Ten 
hydrogen bond acceptors; 3) The molecular 
weight is greater than 500; and 4) Calculated Log 
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P (CLogP) is greater than 5.  Zero violations of 
the rule of five indicates favorable drug likeness, 
with favorable absorption or permeation [24].  
Shown in Table 1, compound 12 demonstrates 
only one violation of the rule of five, however, all 
other compounds demonstrate zero violations.  
This outcome indicates that these aromatic and 
nonaromatic compounds will have favorable 
absorption and membrane permeation. 
 
The molecular properties and MIC (compound 
concentration when only 50% of the bacteria in 
culture are viable) of all compounds are 
presented for comparison in Table 1. A 
multivariate table permits the pattern recognition 
of underlying relationships as well as statistical 
analysis. For all these hydrazide compounds the 
average MIC, formula weight, Log P, and polar 
surface area are 46.15 µgram/mL, 183.55, 0.767, 
and 63.70 Angstroms2, respectively. Notably, 
only compound 12 has one violation of the rule of 
five, whereas, all the others have zero violations, 
indicating favorable drug likeness and favorable 
drug absorption. 
 
The addition of a second hydrazide group           
(-C(=O)-NHNH2) onto the scaffold for compound 
12 increased (doubled) the number of         
hydrogen bond donors (-NHn, -OH) and 
hydrogen bond acceptors (oxygen and nitrogen 
atoms). 
 
These 14 compounds have some level of 
similarity in molecular properties but vary in 
values of MIC. For example, applying the 
Grubb’s test for detecting outliers [25], no outliers 
were found in numerical values of Log P, formula 
weight, and MIC.  Compound 12 is an outlier for 
values of polar surface area, number of –OH and 
–NHn, as well as number of oxygen & nitrogen 
atoms. Interestingly, the sum of five of the 
molecular properties (excluding MIC and rule of 
five) show similar means for these 14 
compounds, a result calculated by one-way 
ANOVA analysis (P = 1.0) [25].  
 
All 14 compounds have been tested by in vitro 
methods for the magnitude of growth inhibition of 
Mycobacterium tuberculosis [13,14,15]. The 
individual MIC values for each compounds is 
presented in Fig. 2 bar graph for comparison to 
isoniazid and other compounds. The overall 
mean for the MIC values obtained from aromatic 
compounds is 47.66 µg/mL, which is very close 
to the average MIC for nonaromatic compounds 
to be 43.43 µg/mL. The overall values of all         
MIC values taken together have no outlier in 
numerical values, determined by Grubb’s test 
[25]. 
 
Interestingly, there appears to be no advantage 
overall in MIC values of either type, aromatic or 
nonaromatic, compared to the other. Although 
the MIC values vary widely individually, from 14.7 
µg/mL (isoniazid) to 100 µg/mL (9 and 10), when 
comparing aromatic and nonaromatic group 
values of MIC, the F and T test and one-way 
ANOVA show that the two group means of MIC 
are equal (P =.82 and P= .82, respectively). In 
addition, the two group values in MIC have equal 
medians by the Mann-Whitney test (P = .68) and 
Kruskal-Wallis test (P = .64) [25].  
 
Therefore, the overall effectiveness of these 
aromatic compounds is considered statistically to 
be essentially equal overall to the nonaromatic 
compounds. However, clearly there are 
substantial improvements in bacterial inhibition, 
indicated by MIC
 
values, from individual drug 
scaffolding and design. For example, clearly for 
aromatic compounds the drugs 14, 8, 3, and 13 
have a substantially lower MIC than compounds 
9 and 10. Likewise, for MIC values for 
nonaromatic compounds, drugs 11, 6, and 7 
have substantially smaller MIC than for 
compound 12 (see Fig. 2). 
 
This study comparing aromatic scaffolding and 
non-aromatic scaffolding clarifies structural 
features important for potential clinical 
application. Even though the aromatic type 
compounds are overall statistically equal to 
nonaromatic compounds, it is still very easy to 
see structure substituents, size in formula weight, 
Log P, and polar surface area can still be 
selected to increase effectiveness in bacterial 
inhibition and smaller MIC. 
 
For example, in the aromatic group of 
compounds the three lowest MIC occur for 
compounds 8, 13, and 14. All three of these 
compounds possess a single pyridine ring with 
the hydrazide group covalently bonded.  
Compounds 8 and 13 have a single methylene 
bridge and 2 methylene bridge groups, 
respectively. Compounds 8 and 13 are two 
members of a homologous series having a 
constant unit of –CH2- [26]. For many series of 
compounds lengthening by adding –CH2- to a 
chain produces an increase in pharmacological 
effects [26]. Although compound 13 has greater 
formula weight than that of compound 8, the 
value of MIC does not increase with an increase 
in formula weight. 
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Table 1. Molecular properties and MIC for compounds 
 
Compound MIC  
(microgram 
per milliliter) 
Formula 
weight 
Log P Polar 
surface 
area 
(Angstroms2) 
Number 
of –OH 
and  
-NHn 
Number of 
oxygen and 
nitrogen 
atoms 
Violations 
of rule of 
5 
1 47.1 150.2 0.721 55.121 3 3 0 
2 38.6 150.2 0.769 55.121 3 3 0 
3 28 150.2 -0.226 55.121 3 3 0 
4 47.1 170.6 0.998 55.121 3 3 0 
5 47.1 209.1 0.258 55.121 3 3 0 
6 26.7 242.41 4.46 55.121 3 3 0 
7 26.7 256.434 4.97 55.121 3 3 0 
8 26.7 151.17 -1.463 68.013 3 4 0 
9 100 220.32 1.874 55.121 3 3 0 
10 100 194.19 0.372 81.426 3 5 0 
11 16.7 214.33 3.449 55.121 3 3 0 
12 100 158.16 -3.52 110.24 6 6 1 
13 26.7 165.2 -0.945 68.013 3 4 0 
14 isoniazid 14.7 137.14 -0.969 68.013 3 4 0 
A2 = Angstroms2 
 
 
 
Fig. 2. Comparison of MIC for compounds 1 to 14 (see Fig. 1). Aromatic compounds have at 
least one aromatic ring. Non-aromatics possess no aromatic ring. Statistical analysis is 
administered to compare results of aromatic and non-aromatic 
 
3.2 Numerical Analysis of Properties 
 
Pattern recognition is the process of classifying 
multivariate data into objects or groups based on 
key properties. There are two classification 
methods in pattern recognition: supervised and 
unsupervised classification [25]. The supervised 
classification of input data into the pattern 
recognition method uses supervised learning 
algorithms that create classifiers based on 
training data. The classifier then accepts input 
data and will assign the object to appropriate 
group [25]. The unsupervised classification 
method works by locating hidden structures in 
unlabeled data by segmentation or clustering 
techniques. 
 
Hierarchical cluster analysis is a method of 
cluster analysis which seeks to build a hierarchy 
of clusters [25]. Objects are classified into 
clusters containing members having highest 
similarity based on properties collected into a 
multivariate table (see Table 1). Hierarchical 
cluster analysis of Table 1 properties, produces 
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the vertical dendrogram results in Fig. 3.  
Conditions of cluster analysis are single-linkage 
clustering (similarity of two clusters is based on 
the similarity of their members) and Euclidean 
distance (straight-line distance between two 
points) [25]. 
 
 
 
Fig. 3. Vertical dendrogram showing results 
of hierarchical cluster analysis of molecular 
properties shown in Table 1. Note initial node 
A is divided to distinguish compound 12 from 
the all the remaining compounds. Node B 
encompasses all other compounds save for 
compound 12 and 10 that are distinguished.  
Within node B the clusters show compounds 
6, 7, and 11 are most similar (with compound 
9 distinct). Node C encompasses cluster 8, 
13, and 14 to be most similar; with cluster 1, 
2, 4, 3, and 5 to be most similar 
 
Beginning with node A containing all compounds, 
they are distinguished into compound 12 
(separate from all others), compound 10, and 
node B. Under node B, there is further distinction 
into compound 9 and cluster of compounds 6, 7, 
and 11 (most similar).  Under node C further 
distinction and classification by similarity shows 
compounds 8, 13, and 14 (most similar).  
Clustering continues with most similar 
compounds 1, 2 (most similar), 4, 3, and 5.  This 
method of numerical analysis shows, based on 
property values, which compounds are most 
similar and potentially equal in activity [26]. 
 
Path analysis is an extension of multiple 
regression. Its aim is to provide estimates of the 
magnitude and significance of hypothesized 
causal connections between sets of properties 
[27]. Path analysis of properties in Table 1 
produced causal connections to MIC presented 
in Fig. 4. By this analysis, clearly the polar 
surface area property has highest causal 
connection to MIC, having path coefficient of 
109.144. Interestingly, the lowest value at -
85.214 is number of oxygen & nitrogen atoms.  
The second to lowest is number of –OH & -NHn 
groups at -29.572. Path analysis can reveal the 
possible causal connections of properties, which 
in turn can indicate causality to MIC. 
 
 
 
Fig. 4. Path analysis of molecular properties 
and their association to MIC values, to 
determine the most influential property.  
Polar surface area is clearly shown to have 
greatest influence to MIC with path coefficient 
of 109.144. Properties quantifying oxygen 
atoms, nitrogen atoms, hydroxyl groups, and 
amine groups are clearly of substantially 
lesser influence (smaller path coefficients) 
 
3.2.1 Multiple regression analysis for 
prediction  
 
Multiple regression is a statistical tool that allows 
you to examine how multiple independent 
variables are related to a dependent variable. 
Once you have identified how these multiple 
variables relate to your dependent variable, you 
can take information about all of the independent 
variables and use it to make much more powerful 
and accurate predictions concerning these 
variables. It is used when we want to predict the 
value of a variable based on the value of two or 
more other variables [25]. 
 
To form a model for prediction and elucidation of 
relations among variables, multiple regress is 
performed utilizing properties in Table 1. The 
result is shown in equation (1) where: FW is 
formula weight, Log P is partition coefficient, PSA 
is polar surface area, nOHNH is number of –OH 
& -NHn groups, and nON is number of oxygen & 
nitrogen atoms.  
 
FW = 98.658 + 18.363(Log P) + 8.473(PSA) 
– 36.858(nOHNH) – 98.129(nON)             (1) 
 
For equation (1), the R2 value is 0.7759, 
indicating 77.59% of the variance in formula 
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weight is explained by the model. In this model, 
the constant 98.658 and Log P make the most 
significant contribution to the model. Here the 
conclusion of the multiple regression is the 
relationship of various properties to the formula 
weight.  
 
Utilizing equation (1), it would be possible to 
predict favorable values of pharmacological 
important properties for perspective drug 
candidates.  The design of new potential drugs 
can be enhanced by targeting the characteristic 
molecular structure of previously successful 
compounds. The design of additional 
tuberculostatic drugs is highly important, the 
appearance of multiple multi-drug resistant 
tuberculosis and extensively drug resistant 
tuberculosis pose a genuine threat to social 
health.  
 
Tuberculosis is a serious health threat and is 
thought to cause up to 1.5 million deaths 
annually [28]. The emergence of drug-resistant 
strains of tuberculosis and with the HIV co-
infection the incidence of this disease has 
increased [28]. Almost one-third of the world’s 
population is infected with Mycobacterium 
tuberculosis [29,30]. Annually, up to 8.8 million 
patients are newly diagnosed with an active 
infection of tuberculosis [30]. The current first-line 
drugs for treatment (isoniazid, rifampin, 
pyrazinamide, ethambutol) must be taken for up 
to 6 months to achieve high level of cure rates 
(>95%) [30]. Clearly, the investigation and 
pursuit of new drugs is vital for the clinical 
treatment of tuberculosis. 
 
4. CONCLUSION 
 
Compounds shown to be effective in inhibiting 
growth of Mycobacterium tuberculosis include 
those that are aromatic (contain conjugated 
planar ring systems) and non-aromatic.  Ranges 
in important properties of these compounds such 
as Log P and polar surface area are broad, from 
-3.52 to 4.97 and 55.12 A2 to 110.24 A2, 
respectively. Ranges of MIC are from 14.7 µg/mL 
for isoniazid to 100 µg/mL for compounds 9 and 
10 (aromatic compounds). Ranges of MIC for 
aromatic and non-aromatic compounds actually 
shows equal group means by F and T test (P = 
.82) and one-way ANOVA (P= .82). Hierarchical 
cluster analysis showed compounds 8 and 13 
are most similar to isoniazid. Path analysis of 
properties showed polar surface area to be most 
direct effect on MIC.  Multiple regression analysis 
indicated that Log P makes the greatest 
contribution within the equation model. This 
study identifies the molecular properties              
and structural features of compounds that     
enable the effective inhibition of Mycobacterium 
tuberculosis.  
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